´ëÇÑÀ忬±¸ÇÐȸ ´ë±¸°æºÏÁöȸ 2021³â Á¦5ȸ ¿¬¼ö°Á : 2021-12-11±³À°ÀÏÀÚ : 2021-12-11
±³À°Àå¼Ò : ±×·£µåÈ£ÅÚ
±³À°ÁÖÁ¦ :
´ëÇÑÀ忬±¸ÇÐȸ ´ë±¸°æºÏÁöȸ 2021³â Á¦5ȸ ¿¬¼ö°ÁÂÁÖÃÖ±â°ü : ´ëÇÑÀ忬±¸ÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ë±¸ °æºÏ Áöȸ
´ã´çÀÚ : ±èÇýÀÎ
¿¬¶ôó : 02-957-6145
À̸ÞÀÏ :
ccaid@naver.com ±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀοø : 100¸í
Èñ¸ÁÆòÁ¡ : 3Á¡
Áö¿ª :
´ë±¸±¤¿ª½Ã±³À°½Ã°£ : 3 ½Ã°£ 40ºÐ
¼¼ºÎ¼ö°·á : 0¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 12-11 ±×·£µåÈ£ÅÚ 14:00~14:20 Strategy when the diagnosis of IBD is not certain ±è°æ¿Á(¿µ³²ÀÇ´ë)
±³À°½Ã°£ 12-11 ±×·£µåÈ£ÅÚ 14:20~14:40 Tips for optimal use of biomarker and endoscopy ÀÌÀ¯Áø(°è¸íÀÇ´ë)
±³À°½Ã°£ 12-11 ±×·£µåÈ£ÅÚ 14:40~15:00 Emerging targets for IBD management: Transmural and Histologic remission ÀÓÁ¾ÇÊ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 12-11 ±×·£µåÈ£ÅÚ 15:00~15:20 Points to consider when selecting biologics in pediatric patients with Crohn¡¯s disease °ºó(°æºÏÀÇ´ë)
±³À°½Ã°£ 12-11 ±×·£µåÈ£ÅÚ 15:20~15:40 Subcutaneous biologics Revisited: What¡¯s different from iv? ÀÌÁØ(Á¶¼±ÀÇ´ë)
ÈÞ½Ä 12-11 ±×·£µåÈ£ÅÚ 15:40~16:00 coffee break ¸ðµçÂü°¡ÀÚ(¸ðµçÂü°¡ÀÚ)
±³À°½Ã°£ 12-11 ±×·£µåÈ£ÅÚ 16:00~16:20 Management of Adverse event associated with IBD medications Á¤À±Áø(´ë±¸ÆÄƼ¸¶º´¿ø)
±³À°½Ã°£ 12-11 ±×·£µåÈ£ÅÚ 16:20~16:40 Talking non-IBD issues with patients with IBD õÀçÈñ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 12-11 ±×·£µåÈ£ÅÚ 16:40~17:05 CD (Crohn¡¯s Disease) ±èÁ¤¼®(°è¸íÀÇ´ë)
±³À°½Ã°£ 12-11 ±×·£µåÈ£ÅÚ 17:05~17:30 UC (Ulcerative Colitis) ±è¹Îö(¿µ³²ÀÇ´ë)
±³À°½Ã°£ 12-11 ±×·£µåÈ£ÅÚ 17:30~18:00 Update in COVID-19 vaccination ±Ç±âÅÂ(°æºÏÀÇ´ë)